Skip to main content

Taysha Gene Therapies, Inc.

TSHA
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001806310

In the last 90 days, Taysha Gene Therapies, Inc. insiders filed 0 open-market purchases and 1 sale; 208 institutions reported holding it in 13F filings for Q2 2026, worth $2.03B in total; no superinvestor holds it.

Q2 2021 vs. Q1 2021

How the institutions holding Taysha Gene Therapies, Inc. changed between Q1 2021 and Q2 2021.

All holders in Q2 2021All holders in Q1 2021

13F holders of TSHA: Q1 2021 compared with Q2 2021
MeasureQ1 2021Q2 2021Change
Holders4649+3
Shares17.7M18.3M+666.9K (+3.8%)
Value$358.5M$388.6M+$30.0M (+8.4%)

New holders (11)

Institutions that held Taysha Gene Therapies, Inc. at the end of Q2 2021 but not at the end of Q1 2021.

Institutions new to TSHA in Q2 2021
InstitutionSharesValue% of portfolio
Granite Point Capital Management, L.P.50,000$1.06M0.31%
Swiss National Bank37,500$795.0K0.00%
Pura Vida Investments, LLC33,822$717.0K0.05%
State of Wisconsin Investment Board28,800$611.0K0.00%
Rhumbline Advisers18,671$396.0K0.00%
Credit Suisse AG13,389$283.0K0.00%
Manufacturers Life Insurance Company, The12,965$275.0K0.00%
D. E. Shaw & Co., Inc.11,448$243.0K0.00%
MetLife Investment Management9,509$201.6K0.00%
Virtus ETF Advisers LLC8,697$184.0K0.08%
Metropolitan Life Insurance Co7,280$154.3K0.00%

Sold out (8)

Institutions that held Taysha Gene Therapies, Inc. at the end of Q1 2021 and filed for Q2 2021 without it.

Institutions that sold out of TSHA in Q2 2021
InstitutionShares, Q1 2021Value, Q1 2021
Casdin Capital, LLC820,440$16.7M
VR Adviser, LLC120,649$2.45M
ArrowMark Colorado Holdings LLC115,723$2.35M
Wells Fargo & Company57,412$1.17M
Alyeska Investment Group, L.P.25,000$508.0K
HRT Financial LP12,239$248.0K
STRS Ohio2,100$42.0K
Bank of Montreal268$5.00K